Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.76
-0.05 (-0.30%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Theravance Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
863948463560755814
Upgrade
Market Cap Growth
107.66%104.89%-17.33%-25.82%-7.35%-28.37%
Upgrade
Enterprise Value
5796604164773201,269
Upgrade
Last Close Price
16.7618.719.4111.2411.2211.05
Upgrade
PE Ratio
8.148.95--0.87-
Upgrade
Forward PE
6.6325.83----
Upgrade
PS Ratio
8.038.827.199.7514.7014.72
Upgrade
PB Ratio
2.883.202.642.631.71-2.40
Upgrade
P/TBV Ratio
2.913.202.642.631.71-
Upgrade
P/FCF Ratio
3.623.98----
Upgrade
P/OCF Ratio
3.623.97----
Upgrade
EV/Sales Ratio
5.396.146.478.306.2322.95
Upgrade
EV/FCF Ratio
2.432.77----
Upgrade
Debt / Equity Ratio
0.140.140.280.230.12-1.98
Upgrade
Debt / FCF Ratio
0.180.18----
Upgrade
Net Debt / Equity Ratio
-0.96-0.96-0.22-0.25-0.62-1.46
Upgrade
Net Debt / EBITDA Ratio
143.61143.610.951.033.62-2.13
Upgrade
Net Debt / FCF Ratio
-1.19-1.193.251.811.47-2.35
Upgrade
Asset Turnover
0.260.260.180.120.110.13
Upgrade
Quick Ratio
10.7310.734.894.8411.993.20
Upgrade
Current Ratio
10.9310.935.025.3912.314.26
Upgrade
Return on Equity (ROE)
44.84%44.84%-29.04%-16.86%-179.84%-
Upgrade
Return on Assets (ROA)
-0.54%-0.54%-7.21%-6.78%-10.07%-35.20%
Upgrade
Return on Invested Capital (ROIC)
--3.66%-28.60%-32.89%-48.85%-200.50%
Upgrade
Return on Capital Employed (ROCE)
-0.80%-0.80%-13.20%-15.00%-13.70%-75.10%
Upgrade
Earnings Yield
12.27%11.17%-12.19%-9.86%115.58%-24.49%
Upgrade
FCF Yield
27.64%25.16%-2.56%-5.27%-24.86%-25.94%
Upgrade
Buyback Yield / Dilution
-5.45%-5.45%11.67%24.85%-5.95%-11.41%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.